TGFB1 and COVID-19: SARS-CoV-2 induces early microthrombosis and immune dysregulation in multiple organs, partly through dysregulated TGF-β1 signaling, which promotes coagulation, immune imbalance, and fibrosis—suggesting that TGF-β inhibitors may offer therapeutic potential in COVID-19-related microvascular complications [131].